Pharma Industry Wants USPTO To Hit Brakes On Changes To Patent Continuation Practice

AbbVie, Amgen, Genentech, Bristol-Myers Squibb and others call on the patent office to retain the current system for continuation applications in comments on the USPTO and FDA’s proposed initiatives.